Clinical Trial Update: A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of Nanrilkefusp Alfa (SOT101) in combination with cetuximab for colorectal cancer has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• Nanrilkefusp Alfa (nanrilkefusp alfa)

Snippet

Sponsor: SOTIO Biotech AG | Conditions: Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-07-24